Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 3
2012 1
2014 2
2015 1
2016 1
2018 1
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.
Bonate PL, Ahamadi M, Budha N, de la Peña A, Earp JC, Hong Y, Karlsson MO, Ravva P, Ruiz-Garcia A, Struemper H, Wade JR. Bonate PL, et al. Among authors: ravva p. J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):123-35. doi: 10.1007/s10928-016-9464-2. Epub 2016 Feb 2. J Pharmacokinet Pharmacodyn. 2016. PMID: 26837775 Review.
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy.
Jordie EB, Gibiansky L, Knab T, Lemenuel-Diot A, Ravva P, Zwanziger E, Jolivet S, Bhardwaj R, Hernández-Sánchez J, Nasmyth-Miller C, Sturm S. Jordie EB, et al. Among authors: ravva p. Br J Clin Pharmacol. 2022 Mar;88(3):1189-1201. doi: 10.1111/bcp.15059. Epub 2021 Oct 15. Br J Clin Pharmacol. 2022. PMID: 34449090 Free article.
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization.
Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Sturm S, et al. Among authors: ravva p. Br J Clin Pharmacol. 2021 Mar;87(3):1359-1368. doi: 10.1111/bcp.14523. Epub 2020 Sep 9. Br J Clin Pharmacol. 2021. PMID: 32808306 Free PMC article.
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Xu C, Ravva P, Dang JS, Laurent J, Adessi C, McIntyre C, Meneses-Lorente G, Mercier F. Xu C, et al. Among authors: ravva p. Cancer Chemother Pharmacol. 2018 Sep;82(3):395-406. doi: 10.1007/s00280-018-3621-9. Epub 2018 Jun 18. Cancer Chemother Pharmacol. 2018. PMID: 29915982
13 results